{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:36:30Z","timestamp":1791999390118,"version":"4.4.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s40263-020-00748-y","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T04:03:57Z","timestamp":1597637037000},"page":"925-946","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":151,"title":["Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies"],"prefix":"10.1007","volume":"34","author":[{"given":"Joost J.","family":"Breeksema","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair R.","family":"Niemeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin","family":"Krediet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0579-4404","authenticated-orcid":false,"given":"Eric","family":"Vermetten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Schoevers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"issue":"3","key":"748_CR1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29(3):289\u201399.","journal-title":"J Psychopharmacol."},{"key":"748_CR2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.neuropharm.2018.01.005","volume":"142","author":"E Dakwar","year":"2018","unstructured":"Dakwar E, Nunes EV, Hart CL, Hu MC, Foltin RW, Levin FR. A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: results from a randomized, controlled laboratory study. Neuropharmacology. 2018;142:270\u20136.","journal-title":"Neuropharmacology"},{"issue":"2","key":"748_CR3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/02791072.1997.10400185","volume":"29","author":"EM Krupitsky","year":"1997","unstructured":"Krupitsky EM, Grinenko AY. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. J Psychoactive Drugs. 1997;29(2):165\u201383.","journal-title":"J Psychoactive Drugs"},{"issue":"11","key":"748_CR4","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983\u201392.","journal-title":"J Psychopharmacol."},{"issue":"1","key":"748_CR5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/0269881112464827","volume":"27","author":"P Oehen","year":"2013","unstructured":"Oehen P, Traber R, Widmer V, Schnyder U. A randomized, controlled pilot study of MDMA (3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharmacol. 2013;27(1):40\u201352.","journal-title":"J Psychopharmacol."},{"issue":"3","key":"748_CR6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/02791072.2008.10400637","volume":"40","author":"JC Bouso","year":"2008","unstructured":"Bouso JC, Doblin R, Farr\u00e9 M, Alc\u00e1zar MA, G\u00f3mez-Jarabo G. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. J Psychoactive Drugs. 2008;40(3):225\u201336.","journal-title":"J Psychoactive Drugs"},{"issue":"12","key":"748_CR7","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1177\/0269881118806297","volume":"32","author":"GM Ot\u2019alora","year":"2018","unstructured":"Ot\u2019alora GM, Grigsby J, Poulter B, Van Derveer JW, Giron SG, Jerome L, et al. 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: a randomized phase 2 controlled trial. J Psychopharmacol. 2018;32(12):1295\u2013307.","journal-title":"J Psychopharmacol."},{"issue":"4","key":"748_CR8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0269881110378371","volume":"25","author":"MC Mithoefer","year":"2011","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of\u2009\u00b1\u20093,4-methylenedioxymethamphetamine- assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol. 2011;25(4):439\u201352.","journal-title":"J Psychopharmacol."},{"issue":"1","key":"748_CR9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0269881112456611","volume":"27","author":"MC Mithoefer","year":"2013","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Martin SF, Yazar-Klosinski B, et al. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol. 2013;27(1):28\u201339.","journal-title":"J Psychopharmacol."},{"issue":"6","key":"748_CR10","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","volume":"5","author":"MC Mithoefer","year":"2018","unstructured":"Mithoefer MC, Mithoefer AT, Feduccia AA, Jerome L, Wagner M, Wymer J, et al. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. The Lancet Psychiatry. 2018;5(6):486\u201397.","journal-title":"The Lancet Psychiatry."},{"issue":"1","key":"748_CR11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","volume":"68","author":"CS Grob","year":"2011","unstructured":"Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68(1):71\u20138.","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"748_CR12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","volume":"202","author":"P Gasser","year":"2014","unstructured":"Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202(7):513\u201320.","journal-title":"J Nerv Ment Dis."},{"issue":"12","key":"748_CR13","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165\u201380.","journal-title":"J Psychopharmacol."},{"issue":"12","key":"748_CR14","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181\u201397.","journal-title":"J Psychopharmacol."},{"issue":"11","key":"748_CR15","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1007\/s00213-018-5010-9","volume":"235","author":"AL Danforth","year":"2018","unstructured":"Danforth AL, Grob CS, Struble CM, Feduccia AA, Walker N, Jerome L, et al. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology. 2018;235(11):3137\u201348.","journal-title":"Psychopharmacology"},{"issue":"11","key":"748_CR16","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","volume":"67","author":"FA Moreno","year":"2006","unstructured":"Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(11):1735\u201340.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"748_CR17","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1017\/S0033291718001356","volume":"49","author":"F Palhano-Fontes","year":"2019","unstructured":"Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49(4):655\u201363.","journal-title":"Psychol Med"},{"issue":"1","key":"748_CR18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1590\/0101-60830000000149","volume":"45","author":"RG dos Santos","year":"2018","unstructured":"dos Santos RG, Sanches RF, de Osorio FL, Hallak JEC. Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up. Arch Clin Psychiatry (S\u00e3o Paulo). 2018;45(1):22\u20134.","journal-title":"Arch Clin Psychiatry (S\u00e3o Paulo)."},{"issue":"1","key":"748_CR19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","volume":"36","author":"RF Sanches","year":"2016","unstructured":"Sanches RF, De Lima Os\u00f3rio F, Santos RGD, Macedo LRH, Maia-De-Oliveira JP, Wichert-Ana L, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression a SPECT study. J Clin Psychopharmacol. 2016;36(1):77\u201381.","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"748_CR20","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry. 2016;3(7):619\u201327.","journal-title":"The Lancet Psychiatry."},{"key":"748_CR21","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.2147\/NDT.S117146","volume":"12","author":"Y Han","year":"2016","unstructured":"Han Y, Chen J, Zou D, Zheng P, Li Q, Wang H, et al. Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies. Neuropsychiatr Dis Treat. 2016;12:2859\u201367.","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"7","key":"748_CR22","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1017\/S0033291716000064","volume":"46","author":"T Kishimoto","year":"2016","unstructured":"Kishimoto T, Chawla JM, Hagi K, Zarate CA Jr, Kane JM, Bauer M, et al. Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med. 2016;46(7):1459\u201372.","journal-title":"Psychol Med"},{"issue":"4","key":"748_CR23","doi-asserted-by":"crossref","first-page":"17m11731","DOI":"10.4088\/JCP.17m11731","volume":"79","author":"ST Wilkinson","year":"2018","unstructured":"Wilkinson ST, Katz RB, Toprak M, Webler R, Ostroff RB, Sanacora G. Acute and longer-term outcomes using ketamine as a clinical treatment at the Yale psychiatric hospital. J Clin Psychiatry. 2018;79(4):17m11731.","journal-title":"J Clin Psychiatry."},{"issue":"2","key":"748_CR24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","volume":"101","author":"DE Nichols","year":"2004","unstructured":"Nichols DE. Hallucinogens. Pharmacol Ther. 2004;101(2):131\u201381.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"748_CR25","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264\u2013355.","journal-title":"Pharmacol Rev"},{"issue":"9","key":"748_CR26","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","volume":"11","author":"FX Vollenweider","year":"2010","unstructured":"Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci. 2010;11(9):642\u201351.","journal-title":"Nat Rev Neurosci"},{"key":"748_CR27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jad.2019.12.023","volume":"264","author":"DS Mathai","year":"2020","unstructured":"Mathai DS, Meyer MJ, Storch EA, Kosten TR. The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: a systematic review. J Affect Disord. 2020;264:123\u20139.","journal-title":"J Affect Disord"},{"issue":"6","key":"748_CR28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ijnp\/pyaa018","volume":"23","author":"E Krediet","year":"2020","unstructured":"Krediet E, Bostoen T, Breeksema J, van Schagen A, Passie T, Vermetten E. Reviewing the potential of psychedelics for the treatment of PTSD. Int J Neuropsychopharmacol. 2020;23(6):385\u2013400.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"974","key":"748_CR29","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fphar.2017.00974","volume":"8","author":"L Roseman","year":"2018","unstructured":"Roseman L, Nutt DJ, Carhart-Harris RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol. 2018;8(974):974.","journal-title":"Front Pharmacol."},{"issue":"7","key":"748_CR30","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1177\/0269881118754710","volume":"32","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL, Roseman L, Haijen E, Erritzoe D, Watts R, Branchi I, et al. Psychedelics and the essential importance of context. J Psychopharmacol. 2018;32(7):725\u201331.","journal-title":"J Psychopharmacol."},{"issue":"12","key":"748_CR31","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1177\/0269881116679368","volume":"30","author":"JJH Rucker","year":"2016","unstructured":"Rucker JJH, Jelen LA, Flynn S, Frowde KD, Young AH. Psychedelics in the treatment of unipolar mood disorders: a systematic review. J Psychopharmacol. 2016;30(12):1220\u20139.","journal-title":"J Psychopharmacol."},{"issue":"3","key":"748_CR32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/2045125316638008","volume":"6","author":"RG dos Santos","year":"2016","unstructured":"dos Santos RG, Os\u00f3rio FL, Crippa JAS, Riba J, Zuardi AW, Hallak JEC. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Ther Adv Psychopharmacol. 2016;6(3):193\u2013213.","journal-title":"Ther Adv Psychopharmacol."},{"issue":"6","key":"748_CR33","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"MW Johnson","year":"2008","unstructured":"Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603\u201320.","journal-title":"J Psychopharmacol."},{"key":"748_CR34","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00005053-196312000-00007","volume":"137","author":"T Leary","year":"1963","unstructured":"Leary T, Lithwin GH, Metzner R. Reactions to psilocybin administered in a supportive environment. J Nerv Ment Dis. 1963;137:561\u201373.","journal-title":"J Nerv Ment Dis."},{"key":"748_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2050324516683325","volume":"3","author":"I Hartogsohn","year":"2017","unstructured":"Hartogsohn I. Constructing drug effects: a history of set and setting. Drug Sci Policy Law. 2017;3:1\u201317.","journal-title":"Drug Sci Policy Law."},{"issue":"12","key":"748_CR36","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1177\/0269881116677852","volume":"30","author":"I Hartogsohn","year":"2016","unstructured":"Hartogsohn I. Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J Psychopharmacol. 2016;30(12):1259\u201367.","journal-title":"J Psychopharmacol."},{"issue":"3","key":"748_CR37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0269881114568040","volume":"29","author":"T Majic","year":"2015","unstructured":"Majic T, Schmidt TT, Gallinat J. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences? J Psychopharmacol. 2015;29(3):241\u201353.","journal-title":"J Psychopharmacol."},{"key":"748_CR38","unstructured":"Kaelen M. The psychological and human brain effects of music in combination with psychedelic drugs, Thesis. London: Imperial College London; 2017. https:\/\/spiral.imperial.ac.uk\/handle\/10044\/1\/55900."},{"key":"748_CR39","volume-title":"A manual for MDMA-assisted psychotherapy in the treatment of posttraumatic stress disorder","author":"MC Mithoefer","year":"2013","unstructured":"Mithoefer MC, Doblin R, Mithoefer A, Jerome L, Ruse J, Gibson E, et al. A manual for MDMA-assisted psychotherapy in the treatment of posttraumatic stress disorder. Santa Cruz: MAPS; 2013."},{"key":"748_CR40","volume-title":"Therapeutic use of ayahuasca","year":"2014","unstructured":"Labate BC, Cavnar C, editors. Therapeutic use of ayahuasca. Berlin: Springer; 2014."},{"issue":"1","key":"748_CR41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jep.2007.08.034","volume":"115","author":"KR Alper","year":"2008","unstructured":"Alper KR, Lotsof HS, Kaplan CD. The ibogaine medical subculture. J Ethnopharmacol. 2008;115(1):9\u201324.","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"748_CR42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/15672050113109990001","volume":"6","author":"TK Brown","year":"2013","unstructured":"Brown TK. Ibogaine in the treatment of substance dependence. Curr Drug Abuse Rev. 2013;6(1):3\u201316.","journal-title":"Curr Drug Abuse Rev."},{"issue":"1","key":"748_CR43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/00952990.2017.1310218","volume":"44","author":"GE Noller","year":"2018","unstructured":"Noller GE, Frampton CM, Yazar-klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37\u201346.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"4","key":"748_CR44","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","volume":"74","author":"G Sanacora","year":"2017","unstructured":"Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017;74(4):399\u2013405.","journal-title":"JAMA Psychiatry."},{"issue":"8","key":"748_CR45","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1177\/0269881117711712","volume":"31","author":"MT Wagner","year":"2017","unstructured":"Wagner MT, Mithoefer MC, Mithoefer AT, MacAulay RK, Jerome L, Yazar-Klosinski B, et al. Therapeutic effect of increased openness: investigating mechanism of action in MDMA-assisted psychotherapy. J Psychopharmacol. 2017;31(8):967\u201374.","journal-title":"J Psychopharmacol."},{"issue":"5","key":"748_CR46","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/acps.12904","volume":"138","author":"D Erritzoe","year":"2018","unstructured":"Erritzoe D, Roseman L, Nour MM, MacLean K, Kaelen M, Nutt DJ, et al. Effects of psilocybin therapy on personality structure. Acta Psychiatr Scand. 2018;138(5):368\u201378.","journal-title":"Acta Psychiatr Scand"},{"issue":"11","key":"748_CR47","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1177\/0269881111420188","volume":"25","author":"KA MacLean","year":"2011","unstructured":"MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. 2011;25(11):1453\u201361.","journal-title":"J Psychopharmacol."},{"issue":"8","key":"748_CR48","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.biopsych.2013.12.015","volume":"78","author":"RL Carhart-Harris","year":"2015","unstructured":"Carhart-Harris RL, Murphy K, Leech R, Erritzoe D, Wall MB, Ferguson B, et al. The effects of acutely administered 3,4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level-dependent resting state functional connectivity. Biol Psychiatry. 2015;78(8):554\u201362.","journal-title":"Biol Psychiatry"},{"issue":"4","key":"748_CR49","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00213-014-3714-z","volume":"232","author":"RL Carhart-Harris","year":"2014","unstructured":"Carhart-Harris RL, Kaelen M, Whalley MG, Bolstridge M, Feilding A, Nutt DJ. LSD enhances suggestibility in healthy volunteers. Psychopharmacology. 2014;232(4):785\u201394.","journal-title":"Psychopharmacology"},{"key":"748_CR50","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3389\/fnins.2018.00129","volume":"12","author":"I Hartogsohn","year":"2018","unstructured":"Hartogsohn I. The meaning-enhancing properties of psychedelics and their mediator role in psychedelic therapy, spirituality, and creativity. Front Neurosci. 2018;12:129.","journal-title":"Front Neurosci."},{"issue":"7\u20138","key":"748_CR51","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/dta.1376","volume":"4","author":"MP Bogenschutz","year":"2012","unstructured":"Bogenschutz MP, Pommy JM. Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses. Drug Test Anal. 2012;4(7\u20138):543\u201355.","journal-title":"Drug Test Anal."},{"issue":"2","key":"748_CR52","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00213-017-4701-y","volume":"235","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris RL, Erritzoe D, Haijen E, Kaelen M, Watts R. Psychedelics and connectedness. Psychopharmacology. 2017;235(2):547\u201350.","journal-title":"Psychopharmacology"},{"issue":"5","key":"748_CR53","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/0022167817709585","volume":"57","author":"R Watts","year":"2017","unstructured":"Watts R, Day C, Krzanowski J, Nutt D, Carhart-Harris R. Patients\u2019 accounts of increased \u201cConnectedness\u201d and \u201cAcceptance\u201d after psilocybin for treatment-resistant depression. J Humanist Psychol. 2017;57(5):520\u201364.","journal-title":"J Humanist Psychol."},{"key":"748_CR54","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jcbs.2019.12.004","volume":"15","author":"R Watts","year":"2020","unstructured":"Watts R, Luoma JB. The use of the psychological flexibility model to support psychedelic assisted therapy. J Context Behav Sci. 2020;15:92\u2013102.","journal-title":"J Context Behav Sci."},{"issue":"9","key":"748_CR55","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1177\/0269881119855974","volume":"33","author":"L Roseman","year":"2019","unstructured":"Roseman L, Haijen E, Idialu-Ikato K, Kaelen M, Watts R, Carhart-Harris R. Emotional breakthrough and psychedelics: validation of the Emotional Breakthrough Inventory. J Psychopharmacol. 2019;33(9):1076\u201387.","journal-title":"J Psychopharmacol."},{"issue":"4","key":"748_CR56","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","volume":"218","author":"RR Griffiths","year":"2011","unstructured":"Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology. 2011;218(4):649\u201365.","journal-title":"Psychopharmacology"},{"issue":"6","key":"748_CR57","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/0269881108094300","volume":"22","author":"RR Griffiths","year":"2008","unstructured":"Griffiths RR, Richards WA, Johnson MW, McCann UD, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14\u00a0months later. J Psychopharmacol. 2008;22(6):621\u201332.","journal-title":"J Psychopharmacol."},{"issue":"3","key":"748_CR58","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s13311-017-0542-y","volume":"14","author":"MW Johnson","year":"2017","unstructured":"Johnson MW, Griffiths RR. Potential therapeutic effects of psilocybin. Neurotherapeutics. 2017;14(3):734\u201340.","journal-title":"Neurotherapeutics."},{"issue":"4","key":"748_CR59","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/09540261.2018.1474185","volume":"30","author":"PS Hendricks","year":"2018","unstructured":"Hendricks PS. Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. Int Rev Psychiatry. 2018;30(4):331\u201342. https:\/\/doi.org\/10.1080\/09540261.2018.1474185.","journal-title":"Int Rev Psychiatry."},{"key":"748_CR60","volume-title":"Qualitative inquiry & research design: choosing among five approaches","author":"JW Creswell","year":"2013","unstructured":"Creswell JW. Qualitative inquiry & research design: choosing among five approaches. 3rd ed. Thousand Oaks: Sage Publications; 2013.","edition":"3"},{"key":"748_CR61","volume-title":"Qualitative methods for health research","author":"J Green","year":"2009","unstructured":"Green J, Thorogood N. Qualitative methods for health research. 2nd ed. London: Sage Publications; 2009.","edition":"2"},{"key":"748_CR62","first-page":"1006","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Med. 2009;62:1006\u201312.","journal-title":"PLoS Med."},{"issue":"4","key":"748_CR63","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/01.NAJ.0000445689.67800.86","volume":"114","author":"BC Stern","year":"2014","unstructured":"Stern BC, Jordan Z. Developing the review question and inclusion criteria. Am J Nurs. 2014;114(4):53\u20136.","journal-title":"Am J Nurs"},{"key":"748_CR64","unstructured":"Niemeijer AR. Exploring good care with surveillance technology in residential care for vulnerable people [PhD thesis]. Amsterdam: Vrije Universiteit Amsterdam; 2015."},{"key":"748_CR65","unstructured":"Barnett-page E, Thomas J. Methods for the synthesis of qualitative research\u202f: a critical review. London; 2009 (NCRM Working Paper Series). Report No. 01\/09. http:\/\/eppi.ioe.ac.uk\/cms\/Default.aspx?tabid=188%0AESRC."},{"issue":"97","key":"748_CR66","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jclinepi.2017.06.020","volume":"97","author":"J Noyes","year":"2018","unstructured":"Noyes J, Booth A, Flemming K, Garside R, Harden A, Lewin S, Pantoja T, Hannes K, Cargo M, Thomas J. Cochrane Qualitative and Implementation Methods Group guidance series\u2014paper 3: methods for assessing methodological limitations, data extraction and synthesis, and confidence in synthesized qualitative findings. J Clin Epidemiol. 2018(97):49\u201358.","journal-title":"J Clin Epidemiol."},{"issue":"3","key":"748_CR67","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/wvn.12134","volume":"13","author":"A Butler","year":"2016","unstructured":"Butler A, Hall RNH, Copnell B. A guide to writing a qualitative systematic review protocol to enhance evidence-based practice in nursing and health care. Worldviews Evid Based Nurs. 2016;13(3):241\u20139.","journal-title":"Worldviews Evid Based Nurs."},{"issue":"2","key":"748_CR68","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jrsm.1128","volume":"6","author":"C Carroll","year":"2015","unstructured":"Carroll C, Booth A. Quality assessment of qualitative evidence for systematic review and synthesis: is it meaningful, and if so, how should it be performed? Res Synth Methods. 2015;6(2):149\u201354.","journal-title":"Res Synth Methods."},{"issue":"1","key":"748_CR69","first-page":"67","volume":"27","author":"R Garside","year":"2014","unstructured":"Garside R. Should we appraise the quality of qualitative research reports for systematic reviews, and if so, how? Innovation. 2014;27(1):67\u201379.","journal-title":"Innovation."},{"issue":"45","key":"748_CR70","first-page":"1","volume":"8","author":"J Thomas","year":"2008","unstructured":"Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Med Res Methodol. 2008;8(45):1\u201310.","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"748_CR71","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol."},{"key":"748_CR72","unstructured":"Lockwood C, Porritt K, Munn Z, Rittenmeyer L, Salmond S, Bjerrum M, et al. Chapter 2: Systematic reviews of qualitative evidence. In: Aromataris E, Munn Z, editors. Joanna Briggs Institute Reviewer\u2019s Manual. The Joanna Briggs Institute; 2017. https:\/\/reviewersmanual.joannabriggs.org\/."},{"key":"748_CR73","unstructured":"Critical Appraisal Skills Programme. CASP Qualitative Checklist. 2018. p. 1\u20136. [cited 12 May 2020]. https:\/\/casp-uk.net\/casp-tools-checklists\/."},{"issue":"4","key":"748_CR74","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/02791072.1986.10472364","volume":"18","author":"G Greer","year":"1986","unstructured":"Greer G, Tolbert R. Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs. 1986;18(4):319\u201327.","journal-title":"J Psychoactive Drugs"},{"issue":"100","key":"748_CR75","first-page":"1","volume":"9","author":"MP Bogenschutz","year":"2018","unstructured":"Bogenschutz MP, Podrebarac SK, Duane JH, Amegadzie SS, Malone TC, Owens LT, et al. Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder. Front Pharmacol. 2018;9(100):1\u20137.","journal-title":"Front Pharmacol."},{"issue":"256","key":"748_CR76","first-page":"1","volume":"9","author":"TC Malone","year":"2018","unstructured":"Malone TC, Mennenga SE, Guss J, Podrebarac SK, Owens LT, Bossis AP, et al. Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy. Front Pharmacol. 2018;9(256):1\u20136.","journal-title":"Front Pharmacol."},{"issue":"132","key":"748_CR77","first-page":"1","volume":"9","author":"EM Nielson","year":"2018","unstructured":"Nielson EM, May DG, Forcehimes AA, Bogenschutz MP. The psychedelic debriefing in alcohol dependence treatment: illustrating key change phenomena through qualitative content analysis of clinical sessions. Front Pharmacol. 2018;9(132):1\u201313.","journal-title":"Front Pharmacol."},{"issue":"1","key":"748_CR78","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1556\/2054.01.2016.002","volume":"1","author":"EE Schenberg","year":"2017","unstructured":"Schenberg EE, de Castro Comis MA, Alexandre JFM, Rasmussen Chaves BD, T\u00f3foli LF, da Silveira DX. Treating drug dependence with the aid of ibogaine: a qualitative study. J Psychedelic Stud. 2017;1(1):10\u20139.","journal-title":"J Psychedelic Stud."},{"issue":"2","key":"748_CR79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1556\/2054.01.2017.007","volume":"1","author":"EE Schenberg","year":"2017","unstructured":"Schenberg EE, de Castro Comis MA, Alexandre JFM, T\u00f3foli LF, Rasmussen Chaves BD, da Silveira DX. A phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatment. J Psychedelic Stud. 2017;1(2):1\u201310.","journal-title":"J Psychedelic Stud."},{"issue":"2","key":"748_CR80","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/02791072.2019.1580805","volume":"51","author":"W Barone","year":"2019","unstructured":"Barone W, Beck J, Mitsunaga-Whitten M, Perl P. Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: qualitative follow-up study of a clinical trial for individuals with treatment-resistant PTSD. J Psychoactive Drugs. 2019;51(2):199\u2013208.","journal-title":"J Psychoactive Drugs"},{"issue":"5","key":"748_CR81","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1177\/0022167817715966","volume":"57","author":"TC Swift","year":"2017","unstructured":"Swift TC, Belser AB, Agin-Liebes G, Devenot NN, Terrana S, Friedman HL, et al. Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress. J Humanist Psychol. 2017;57(5):488\u2013519.","journal-title":"J Humanist Psychol."},{"issue":"4","key":"748_CR82","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1177\/0022167817706884","volume":"57","author":"AB Belser","year":"2017","unstructured":"Belser AB, Agin-Liebes G, Swift TC, Terrana S, Devenot N, Friedman HL, et al. Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis. J Humanist Psychol. 2017;57(4):354\u201388.","journal-title":"J Humanist Psychol."},{"issue":"7","key":"748_CR83","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1177\/0269881118780612","volume":"32","author":"T Noorani","year":"2018","unstructured":"Noorani T, Garcia-Romeu A, Swift TC, Griffiths RR, Johnson MW. Psychedelic therapy for smoking cessation: qualitative analysis of participant accounts. J Psychopharmacol. 2018;32(7):756\u201369.","journal-title":"J Psychopharmacol."},{"key":"748_CR84","first-page":"6","volume":"227","author":"GI van Schalkwyk","year":"2017","unstructured":"van Schalkwyk GI, Wilkinson ST, Davidson L, Silverman WK, van Sanacora GGIS, et al. Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: analysis of the Clinician Administered Dissociative State Scale. J Affect Disord. 2017;227:6\u201311.","journal-title":"J Affect Disord."},{"issue":"1","key":"748_CR85","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0269881114555249","volume":"29","author":"P Gasser","year":"2015","unstructured":"Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol. 2015;29(1):57\u201368.","journal-title":"J Psychopharmacol."},{"issue":"1","key":"748_CR86","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1556\/2054.2018.004","volume":"2","author":"TJ Camlin","year":"2018","unstructured":"Camlin TJ, Eulert D, Thomas Horvath A, Bucky SF, Barsuglia JP, Polanco M. A phenomenological investigation into the lived experience of ibogaine and its potential to treat opioid use disorders. J Psychedelic Stud. 2018;2(1):24\u201335.","journal-title":"J Psychedelic Stud."},{"issue":"5","key":"748_CR87","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/02791072.2017.1361559","volume":"49","author":"A Lafrance","year":"2017","unstructured":"Lafrance A, Loizaga-Velder A, Fletcher J, Renelli M, Files N, Tupper KW, et al. Nourishing the spirit: exploratory research on ayahuasca experiences along the continuum of recovery from eating disorders. J Psychoactive Drugs. 2017;49(5):427\u201335.","journal-title":"J Psychoactive Drugs"},{"issue":"2","key":"748_CR88","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40519-018-0619-6","volume":"25","author":"M Renelli","year":"2020","unstructured":"Renelli M, Fletcher J, Tupper KW, Files N, Loizaga-Velder A, Lafrance A. An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders. Eat Weight Disord. 2020;25(2):437\u201344.","journal-title":"Eat Weight Disord."},{"key":"748_CR89","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drugpo.2017.02.017","volume":"44","author":"P Talin","year":"2017","unstructured":"Talin P, Sanabria E. Ayahuasca\u2019s entwined efficacy: an ethnographic study of ritual healing from \u2018addiction\u2019. Int J Drug Policy. 2017;44:23\u201330.","journal-title":"Int J Drug Policy."},{"issue":"1","key":"748_CR90","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/02791072.2013.873157","volume":"46","author":"A Loizaga-Velder","year":"2014","unstructured":"Loizaga-Velder A, Verres R. Therapeutic effects of ritual ayahuasca use in the treatment of substance dependence: qualitative results. J Psychoactive Drugs. 2014;46(1):63\u201372.","journal-title":"J Psychoactive Drugs"},{"issue":"5","key":"748_CR91","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/0022167817709585","volume":"57","author":"R Watts","year":"2017","unstructured":"Watts R, Day C, Krzanowski J, Nutt D, Carhart-Harris R. Patients\u2019 accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression. J Hum Psychol. 2017;57(5):520\u201364.","journal-title":"J Hum Psychol."},{"key":"748_CR92","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.brainresbull.2016.05.016","volume":"126","author":"Y Liu","year":"2016","unstructured":"Liu Y, Lin D, Wu B, Zhou W. Ketamine abuse potential and use disorder. Brain Res Bull. 2016;126:68\u201373.","journal-title":"Brain Res Bull"},{"key":"748_CR93","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1360-0443.2011.03576.x","volume":"107","author":"CJA Morgan","year":"2011","unstructured":"Morgan CJA, Curran HV. Ketamine use: a review. Addiction. 2011;107:27\u201338.","journal-title":"Addiction."},{"issue":"2","key":"748_CR94","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1874473708666150107120011","volume":"7","author":"MJ Winkelman","year":"2014","unstructured":"Winkelman MJ. Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, peyote, ibogaine and ayahuasca. Curr Drug Abuse Rev. 2014;7(2):101\u201316.","journal-title":"Curr Drug Abuse Rev."},{"key":"748_CR95","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1192\/bjp.186.3.182","volume":"186","author":"M Maj","year":"2005","unstructured":"Maj M. \u201cPsychiatric comorbidity\u201d: an artefact of current diagnostic systems? Br J Psychiatry. 2005;186:182\u20134.","journal-title":"Br J Psychiatry"},{"issue":"6395","key":"748_CR96","doi-asserted-by":"crossref","first-page":"eaap8757","DOI":"10.1126\/science.aap8757","volume":"360","author":"The Brainstorm Consortium","year":"2018","unstructured":"The Brainstorm Consortium. Analysis of shared heritability in common disorders of the brain. Science. 2018;360(6395):eaap8757.","journal-title":"Science."},{"issue":"7","key":"748_CR97","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1176\/appi.ajp.2010.09091379","volume":"167","author":"T Insel","year":"2010","unstructured":"Insel T, Cuthbert B, Garvey M, Heinssen R, Pine D, Quinn K, et al. Research Domain Criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry Online. 2010;167(7):748\u201351.","journal-title":"Am J Psychiatry Online."},{"key":"748_CR98","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1176\/appi.ajp.160.1.4","volume":"160","author":"R Kendell","year":"2003","unstructured":"Kendell R, Jablensky A. Distinguishing between the validity and utility of psychiatric diagnoses. Am J Psychiatry. 2003;160:4\u201312.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"748_CR99","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/wps.20284","volume":"15","author":"A Jablensky","year":"2016","unstructured":"Jablensky A. Psychiatric classifications: validity and utility. World Psychiatry. 2016;15(1):26\u201331.","journal-title":"World Psychiatry."},{"issue":"8","key":"748_CR100","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1176\/appi.ajp.2016.15121509","volume":"173","author":"KS Kendler","year":"2016","unstructured":"Kendler KS. The phenomenology of major depression and the representativeness and nature of DSM criteria. Am J Psychiatry. 2016;173(8):771\u201380.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"748_CR101","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41380-017-0010-4","volume":"24","author":"JW Smoller","year":"2019","unstructured":"Smoller JW, Andreassen OA, Edenberg HJ, Faraone SV, Glatt SJ, Kendler KS. Psychiatric genetics and the structure of psychopathology. Mol Psychiatry. 2019;24(3):409\u201320.","journal-title":"Mol Psychiatry."},{"key":"748_CR102","first-page":"67","volume-title":"Psychedelic medicine: new evidence for hallucinogenic substances as treatments","author":"E Krupitsky","year":"2007","unstructured":"Krupitsky E, Kolp E, Winkelman MJ, Roberts TB. Ketamine psychedelic psychotherapy. In: Winkelman MJ, Roberts TB, editors. Psychedelic medicine: new evidence for hallucinogenic substances as treatments, vol. 2. Westport, CT: Praeger Publishers\/Greenwood Publishing Group; 2007. p. 67\u201385."},{"key":"748_CR103","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/7854_2017_34","volume-title":"Behavioral neurobiology of PTSD","author":"C Veen","year":"2018","unstructured":"Veen C, Jacobs G, Philippens I, Vermetten E. Subanesthetic dose ketamine in posttraumatic stress disorder: a role for reconsolidation during trauma-focused psychotherapy? In: Vermetten E, Baker DG, Risbrough VB, editors. Behavioral neurobiology of PTSD. Cham: Springer International Publishing; 2018. p. 137\u201362."},{"issue":"11","key":"748_CR104","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1176\/appi.ajp.2019.18101123","volume":"176","author":"E Dakwar","year":"2019","unstructured":"Dakwar E, Nunes EV, Hart CL, Foltin RW, Mathew SJ, Carpenter KM, et al. A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial. Am J Psychiatry. 2019;176(11):923\u201330.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"748_CR105","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/09540261.2018.1484342","volume":"30","author":"FS Barrett","year":"2018","unstructured":"Barrett FS, Preller KH, Kaelen M. Psychedelics and music: neuroscience and therapeutic implications. Int Rev Psychiatry. 2018;30(4):350\u201362.","journal-title":"Int Rev Psychiatry."},{"issue":"2","key":"748_CR106","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-017-4820-5","volume":"235","author":"M Kaelen","year":"2018","unstructured":"Kaelen M, Giribaldi B, Raine J, Evans L, Timmermann C, Rodriguez N, et al. The hidden therapist: evidence for a central role of music in psychedelic therapy. Psychopharmacology. 2018;235(2):505\u201319.","journal-title":"Psychopharmacology"},{"issue":"1","key":"748_CR107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.clinpsy.3.022806.091432","volume":"3","author":"AE Kazdin","year":"2007","unstructured":"Kazdin AE. Mediators and mechanisms of change in psychotherapy research. Annu Rev Clin Psychol. 2007;3(1):1\u201327.","journal-title":"Annu Rev Clin Psychol."},{"issue":"1","key":"748_CR108","first-page":"3","volume":"11","author":"WN Pahnke","year":"1970","unstructured":"Pahnke WN. The psychedelic mystical experience in the human encounter with death. Psychedelic Rev. 1970;11(1):3\u201320.","journal-title":"Psychedelic Rev."},{"issue":"1","key":"748_CR109","first-page":"1","volume":"9","author":"WA Richards","year":"1977","unstructured":"Richards WA, Rhead JC, Dileo FB, Yensen R, Kurland AA. The peak experience variable in DPT-assisted psychotherapy with cancer patients. J Psychoactive Drugs. 1977;9(1):1\u201310.","journal-title":"J Psychoactive Drugs"},{"issue":"3","key":"748_CR110","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000467984","volume":"8","author":"S Grof","year":"1973","unstructured":"Grof S, Goodman LE, Richards WA, Kurland AA. LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry. 1973;8(3):129\u201344.","journal-title":"Int Pharmacopsychiatry."},{"issue":"1","key":"748_CR111","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.drugalcdep.2013.12.019","volume":"136","author":"E Dakwar","year":"2014","unstructured":"Dakwar E, Anerella C, Hart CL, Levin FR, Mathew SJ, Nunes EV. Therapeutic infusions of ketamine: do the psychoactive effects matter? Drug Alcohol Depend. 2014;136(1):153\u20137.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"748_CR112","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1874473708666150107121331","volume":"7","author":"A Garcia-Romeu","year":"2014","unstructured":"Garcia-Romeu A, Griffiths RR, Johnson MW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev. 2014;7(3):157\u201364.","journal-title":"Curr Drug Abuse Rev."},{"key":"748_CR113","first-page":"221","volume-title":"current topics in behavioral neurosciences behavioral neurobiology of psychedelic drugs","author":"KH Preller","year":"2018","unstructured":"Preller KH, Vollenweider FX. Phenomenology, structure, and dynamic of psychedelic states. In: Halberstadt AL, Vollenweider FX, Nichols DE, editors. current topics in behavioral neurosciences behavioral neurobiology of psychedelic drugs. 1st ed. Berlin: Springer-Verlag GmbH; 2018. p. 221\u201356.","edition":"1"},{"key":"748_CR114","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.paid.2017.06.004","volume":"117","author":"FS Barrett","year":"2017","unstructured":"Barrett FS, Johnson MW, Griffiths RR. Neuroticism is associated with challenging experiences with psilocybin mushrooms. Pers Individ Dif. 2017;117:155\u201360.","journal-title":"Pers Individ Dif."},{"issue":"12","key":"748_CR115","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0269881116678781","volume":"30","author":"FS Barrett","year":"2016","unstructured":"Barrett FS, Bradstreet MP, Leoutsakos J-MS, Johnson MW, Griffiths RR. The challenging experience questionnaire: characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol. 2016;30(12):1279\u201395.","journal-title":"J Psychopharmacol."},{"issue":"12","key":"748_CR116","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0269881116662634","volume":"30","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol. 2016;30(12):1268\u201378.","journal-title":"J Psychopharmacol."},{"issue":"1","key":"748_CR117","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/00952990.2017.1320802","volume":"44","author":"TK Brown","year":"2018","unstructured":"Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24\u201336.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"1\u20132","key":"748_CR118","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.drugalcdep.2011.12.007","volume":"122","author":"Oortmerssen K van Emmerik-van","year":"2012","unstructured":"van Emmerik-van Oortmerssen K, van de Glind G, van den Brink W, Smit F, Crunelle CL, Swets M, et al. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug Alcohol Depend. 2012;122(1\u20132):11\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"748_CR119","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00406-017-0801-2","volume":"268","author":"UW Preuss","year":"2018","unstructured":"Preuss UW, Gouzoulis-Mayfrank E, Havemann-Reinecke U, Sch\u00e4fer I, Beutel M, Hoch E, et al. Psychiatric comorbidity in alcohol use disorders: results from the German S3 guidelines. Eur Arch Psychiatry Clin Neurosci. 2018;268(3):219\u201329.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"4","key":"748_CR120","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/dar.12448","volume":"36","author":"REF Kingston","year":"2017","unstructured":"Kingston REF, Marel C, Mills KL. A systematic review of the prevalence of comorbid mental health disorders in people presenting for substance use treatment in Australia. Drug Alcohol Rev. 2017;36(4):527\u201339.","journal-title":"Drug Alcohol Rev."},{"issue":"6","key":"748_CR121","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/09595230600944461","volume":"25","author":"E Jan\u00e9-Llopis","year":"2006","unstructured":"Jan\u00e9-Llopis E, Matytsina I. Mental health and alcohol, drugs and tobacco: a review of the comorbidity between mental disorders and the use of alcohol, tobacco and illicit drugs. Drug Alcohol Rev. 2006;25(6):515\u201336.","journal-title":"Drug Alcohol Rev."},{"key":"748_CR122","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.neulet.2016.07.004","volume":"649","author":"B Sessa","year":"2017","unstructured":"Sessa B. MDMA and PTSD treatment: \u201cPTSD: from novel pathophysiology to innovative therapeutics\u201d. Neurosci Lett. 2017;649:176\u201380.","journal-title":"Neurosci Lett"},{"issue":"14","key":"748_CR123","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1073\/pnas.1618569114","volume":"114","author":"D Fanelli","year":"2017","unstructured":"Fanelli D, Costas R, Ioannidis JPA. Meta-assessment of bias in science. Proc Natl Acad Sci USA. 2017;114(14):3714\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"748_CR124","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cpt.557","volume":"101","author":"DE Nichols","year":"2017","unstructured":"Nichols DE, Johnson MW, Nichols CD. Psychedelics as medicines: an emerging new paradigm. Clin Pharmacol Ther. 2017;101(2):209\u201319.","journal-title":"Clin Pharmacol Ther"},{"issue":"6234","key":"748_CR125","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1126\/science.aab2358","volume":"348","author":"T Insel","year":"2015","unstructured":"Insel T, Cuthbert B. Brain disorders? Precisely. Science. 2015;348(6234):499\u2013500.","journal-title":"Science."},{"issue":"9","key":"748_CR126","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1176\/appi.ajp.2018.17121383","volume":"175","author":"A Caspi","year":"2018","unstructured":"Caspi A, Moffitt TE. All for one and one for all: mental disorders in one dimension. Am J Psychiatry. 2018;175(9):831\u201344.","journal-title":"Am J Psychiatry"},{"issue":"4\u20135","key":"748_CR127","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/10503300802448899","volume":"19","author":"AE Kazdin","year":"2009","unstructured":"Kazdin AE. Understanding how and why psychotherapy leads to change. Psychother Res. 2009;19(4\u20135):418\u201328.","journal-title":"Psychother Res."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00748-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-020-00748-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00748-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T19:31:41Z","timestamp":1629142301000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-020-00748-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":127,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["748"],"URL":"https:\/\/doi.org\/10.1007\/s40263-020-00748-y","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,17]]},"assertion":[{"value":"17 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Robert A. Schoevers received a research grant from the Netherlands Organization Health Research and Development for a clinical study on oral esketamine, and is the co-investigator of a clinical study on psilocybin funded by Compass Pathways. He has also received an educational grant from Janssen, Pharmaceutical Companies of Johnson and Johnson, and honorarium from Clexio Biosciences. Eric Vermetten is the principal investigator of a clinical trial on MDMA funded by the Multidisciplinary Association for Psychedelic Studies. Joost J. Breeksema, Alistair R. Niemeijer and Erwin Krediet declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was made possible in part thanks to support from the Nypels-Tans PTSD fund at the Leiden University Medical Center. The fund had no role in the study design, collection, analysis or interpretation of the data, writing the manuscript, or the decision to submit the paper for publication. This article was published open access thanks to an agreement between Springer Nature and the University Medical Center Groningen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and codes"}},{"value":"JJB designed the study and conducted all literature searches. All articles were read and re-read closely by the first author. Primary analysis, categorization and extraction of relevant themes and quotes was also performed by JJB. Further iterations of categories were discussed between all authors. The final manuscript was written by JJB, and all authors contributed to and have approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}